Literature DB >> 23541881

TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production.

Michael J Brumlik1, Srilakshmi Pandeswara, Sara M Ludwig, Duane P Jeansonne, Michelle R Lacey, Kruthi Murthy, Benjamin J Daniel, Rong-Fu Wang, Suzanne R Thibodeaux, Kristina M Church, Vincent Hurez, Mark J Kious, Bin Zhang, Adebusola Alagbala, Xiaojun Xia, Tyler J Curiel.   

Abstract

The parasite Toxoplasma gondii controls tissue-specific nitric oxide (NO), thereby augmenting virulence and immunopathology through poorly-understood mechanisms. We now identify TgMAPK1, a Toxoplasma mitogen-activated protein kinase (MAPK), as a virulence factor regulating tissue-specific parasite burden by manipulating host interferon (IFN)-γ-mediated inducible nitric oxide synthase (iNOS). Toxoplasma with reduced TgMAPK1 expression (TgMAPK1(lo)) demonstrated that TgMAPK1 facilitates IFN-γ-driven p38 MAPK activation, reducing IFN-γ-generated NO in an MKK3-dependent manner, blunting IFN-γ-mediated parasite control. TgMAPK1(lo) infection in wild type mice produced ≥ten-fold lower parasite burden versus control parasites with normal TgMAPK1 expression (TgMAPK1(con)). Reduced parasite burdens persisted in IFN-γ KO mice, but equalized in normally iNOS-replete organs from iNOS KO mice. Parasite MAPKs are far less studied than other parasite kinases, but deserve additional attention as targets for immunotherapy and drug discovery.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541881      PMCID: PMC4226171          DOI: 10.1016/j.exppara.2013.03.016

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  46 in total

Review 1.  Toxoplasma gondii: the model apicomplexan.

Authors:  Kami Kim; Louis M Weiss
Journal:  Int J Parasitol       Date:  2004-03-09       Impact factor: 3.981

2.  p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes.

Authors:  Felix B Engel; Michael Schebesta; Mychelle T Duong; Gang Lu; Shuxun Ren; Jeffery B Madwed; Huiping Jiang; Yibin Wang; Mark T Keating
Journal:  Genes Dev       Date:  2005-05-03       Impact factor: 11.361

Review 3.  Kiss and spit: the dual roles of Toxoplasma rhoptries.

Authors:  John C Boothroyd; Jean-Francois Dubremetz
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

4.  In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection.

Authors:  T M Scharton-Kersten; T A Wynn; E Y Denkers; S Bala; E Grunvald; S Hieny; R T Gazzinelli; A Sher
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

5.  Consensus sequence of translational initiation sites from Toxoplasma gondii genes.

Authors:  F Seeber
Journal:  Parasitol Res       Date:  1997       Impact factor: 2.289

Review 6.  The role of gamma interferon in antimicrobial immunity.

Authors:  R Shtrichman; C E Samuel
Journal:  Curr Opin Microbiol       Date:  2001-06       Impact factor: 7.934

7.  A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice.

Authors:  I A Khan; J D Schwartzman; T Matsuura; L H Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 8.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

9.  Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation.

Authors:  R T Gazzinelli; I Eltoum; T A Wynn; A Sher
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

10.  Disruption of Toxoplasma gondii parasitophorous vacuoles by the mouse p47-resistance GTPases.

Authors:  Sascha Martens; Iana Parvanova; Jens Zerrahn; Gareth Griffiths; Gudrun Schell; Gaby Reichmann; Jonathan C Howard
Journal:  PLoS Pathog       Date:  2005-11-18       Impact factor: 6.823

View more
  7 in total

Review 1.  Toxoplasma gondii development of its replicative niche: in its host cell and beyond.

Authors:  Ira J Blader; Anita A Koshy
Journal:  Eukaryot Cell       Date:  2014-06-20

2.  Deletion of mitogen-activated protein kinase 1 inhibits development and growth of Toxoplasma gondii.

Authors:  Lili Cao; Zedong Wang; Shuchao Wang; Jiping Li; Xinglong Wang; Feng Wei; Quan Liu
Journal:  Parasitol Res       Date:  2015-11-02       Impact factor: 2.289

3.  A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle.

Authors:  Tatsuki Sugi; Shin-Ichiro Kawazu; Taisuke Horimoto; Kentaro Kato
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-12-19       Impact factor: 4.077

Review 4.  Potential Sabotage of Host Cell Physiology by Apicomplexan Parasites for Their Survival Benefits.

Authors:  Shalini Chakraborty; Sonti Roy; Hiral Uday Mistry; Shweta Murthy; Neena George; Vasundhra Bhandari; Paresh Sharma
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

5.  Genome-Wide Identification and Evolutionary Analysis of Sarcocystis neurona Protein Kinases.

Authors:  Edwin K Murungi; Henry M Kariithi
Journal:  Pathogens       Date:  2017-03-21

6.  Forward genetic screening identifies a small molecule that blocks Toxoplasma gondii growth by inhibiting both host- and parasite-encoded kinases.

Authors:  Kevin M Brown; Elena Suvorova; Andrew Farrell; Aaron McLain; Ashley Dittmar; Graham B Wiley; Gabor Marth; Patrick M Gaffney; Marc Jan Gubbels; Michael White; Ira J Blader
Journal:  PLoS Pathog       Date:  2014-06-12       Impact factor: 6.823

Review 7.  Toxoplasmosis: Current and Emerging Parasite Druggable Targets.

Authors:  Rana El Hajj; Lina Tawk; Shaymaa Itani; Maguy Hamie; Jana Ezzeddine; Marwan El Sabban; Hiba El Hajj
Journal:  Microorganisms       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.